Karen Lay, a 56-year-old from Essex, spent approximately £4,100 on prescription weight loss injections, Wegovy and Mounjaro, over 15 months, only to achieve minimal results.
Ms. Lay began using Wegovy in late 2023 due to what she described as "sheer desperation" after trying various diets. While her appetite reduced slightly, the effect was not significant enough to warrant the cost and effort. After nine months on Wegovy, she switched to Mounjaro, sometimes referred to as the "King-Kong" of weight loss injections. During the six months she used Mounjaro, she reported "barely eating" but still only lost seven pounds.
This experience contrasts sharply with clinical trial expectations for these medications. Trials suggest that Wegovy users can typically lose around 21 percent of their body weight after 72 weeks, with Mounjaro users expecting to lose approximately 22.5 percent over the same period. Ms. Lay's doctor advised her to stop the injections due to concerns about her insufficient food intake.
Her journey with the drugs was emotionally taxing, especially when she had to pause treatment for four weeks between medications. During this period, she experienced overwhelming "food noise" and gained over seven pounds. The perceived success of others on the same medications, losing substantial weight while she struggled, led to feelings of failure and self-doubt.
Upon discontinuing the injections, Ms. Lay adopted a diet plan known as the 1:1 Diet Plan, which focuses on very low-calorie meals and personalized advice from nutrition advisors. Within a year of starting this plan, she lost two stone, dropping from a dress size 18 to a size 12, her smallest size in 17 years. She now feels healthier and more energetic than when she was taking the weight loss injections.
Ms. Lay believes a common misconception is that these injections are a guaranteed solution for weight loss. She stated that while they work well for some, they are not effective for everyone. For her, the success came from "proper nutrition, structure, accountability, and rebuilding my relationship with food."
Research indicates that a portion of individuals using GLP-1 receptor agonists, the class of drugs that includes Wegovy and Mounjaro, may be "non-responders," failing to achieve significant weight loss. Experts suggest that individual metabolic responses, or the body's natural defense mechanisms against calorie reduction, can influence weight loss outcomes, meaning not everyone reacts to the drugs in the same way.
Ms. Lay also noted that as her health improved with proper nutrition and weight loss, the need for some of her other medications, including asthma treatment, decreased or ceased altogether.
It is estimated that around 2.5 million adults in the UK are currently using weight loss injections, with the newly approved Wegovy pill recently rolling out in Britain.